Evidence map›Paper›PMID 40657304›Full record

ArticleHemaSphere2025

PRC2-mediated apoptosis evasion is a therapeutic target of MDS/AML harboring inv(3)/t(3;3) and monosomy 7.

Hiroyoshi Kunimoto, Ayaka Miura, Maiko Sagisaka, Mieko Ito, Ryoichi Maenosono, Hirofumi Yamauchi, Kazuki Nishimura, Daisuke Honma, Shinji Tsutsumi, Akiko Adachi and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Hiroyoshi KunimotoDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.ORCID https://orcid.org/0009-0005-0511-2583
Ayaka MiuraDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
Maiko SagisakaClinical Research Institute Kanagawa Children's Medical Center Yokohama Japan.
Mieko ItoClinical Research Institute Kanagawa Children's Medical Center Yokohama Japan.
Ryoichi MaenosonoDivision of Cancer RNA Research National Cancer Center Research Institute Tokyo Japan.
Hirofumi YamauchiDivision of Cancer RNA Research National Cancer Center Research Institute Tokyo Japan.
Kazuki NishimuraDivision of Cancer RNA Research National Cancer Center Research Institute Tokyo Japan.
Daisuke HonmaModality Research Laboratories III, Daiichi Sankyo Co. Ltd. Tokyo Japan.
Shinji TsutsumiTranslational Science Oncology, Daiichi Sankyo, Inc. Basking Ridge New Jersey USA.
Akiko AdachiDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
Takayuki SakumaDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
Takuma OhashiDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
Hiroshi TeranakaDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
Junji IkedaDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.ORCID https://orcid.org/0000-0001-6629-5006
Sei SamukawaDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.
Takashi ToyaHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan.
Yuka HaradaClinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital Tokyo Japan.
Sheng F CaiLeukemia Service, Department of Medicine, Center for Hematologic Malignancies Memorial Sloan Kettering Cancer Center New York New York USA.
Hiroaki MakiDepartment of Hematology and Oncology, Graduate School of Medicine University of Tokyo Tokyo Japan.
Hiroaki GotoClinical Research Institute Kanagawa Children's Medical Center Yokohama Japan.
Akihide YoshimiDivision of Cancer RNA Research National Cancer Center Research Institute Tokyo Japan.
Hideaki NakajimaDepartment of Stem Cell and Immune Regulation Yokohama City University Graduate School of Medicine Yokohama Japan.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) harboring both inv(3)/t(3;3) and monosomy 7 (-7) are highly aggressive myeloid cancers of which molecular pathogenesis and therapeutic vulnerability remain elusive. High throughput drug screens, CUT&Tag/RNA sequence, and functional assays using human MDS/AML cells revealed that EZH2 inhibitors efficiently induce apoptosis preferentially in MDS/AML with inv(3)/t(3;3) and -7 through the activation of GADD45γ-p38-p53 axis. EVI1 activated in 3q-rearranged MDS/AML was responsible for

Identifiers

PMID40657304
PMCPMC12255905

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.